Ann: Quarterly Activity Report & Appendix 4C, page-40

The lowest of low hanging fruit would be to just assay for insulin before and after giving Zantrene in the EMD AML trial. The patients in Stratum 2 are very likely to have Type 2 diabetes given their age and their unsuitability for high intensity chemotherapy - my rough guess is between 30-50% will be either diabetic or pre-diabetic.

We will be collecting blood from the patients anyway so it is just a matter of running some of the blood through a standard assay for insulin. It would likely only cost a couple of hundred dollars extra per patient to assay for insulin even taking into account the usual inflated clinical trial costs. Imagine if we find that Zantrene does positively impact insulin secretion in humans at low doses.